ECIA
Encision Inc.0.1500
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.53MP/E (TTM)
-Basic EPS (TTM)
-0.03Dividend Yield
0%Recent Filings
8-K
CEO Trudel resigns abruptly
Encision's board ousted Gregory Trudel as director, CEO, and president on December 8, 2025, over disagreements on the company's future direction. No operational disputes noted. Board tapped long-time director Robert Fries, 77, a veteran finance exec and consultant, as interim CEO. Leadership shakeup tests strategic continuity.
10-Q
Q2 FY2026 results
Encision's Q2 FY2026 revenue fell 13% y/y to $1.5M (product down 10% to $1.5M, service down 54% to $46K), while gross margin held at 46% versus 47%. Operating loss widened to $258K from $159K as R&D rose 30%, yet sales/marketing and G&A dipped. YTD revenue dropped 8% to $3.1M, net loss to $309K ($0.02/share on 13M shares); EPS reconciles. Cash burned to $72K amid $242K operating outflow, offset by $500K stock issuance; line of credit at $32K with $968K availability, secured notes $197K. Cash won't last. FDA inspections loom.
8-K
Encision secures $500K funding
Encision Inc. closed a $500,000 private placement on August 19, 2025, issuing 5 million common shares at $0.10 each to accredited investors, including directors, executives, and new shareholders. The funds will support ongoing operations and the early 2026 launch of a new ENT device. This bolsters liquidity while diluting existing shareholders. Yet risks like product acceptance loom large.
10-Q
Q1 FY2026 results
Encision's Q1 FY2026 revenue dipped 1.7% y/y to $1.6M, with product sales down 6% to $1.5M from fewer procedures, yet service revenue surged over 180% to $0.1M via a Vicarious Surgical deal. Gross profit fell 7% to $0.9M, trimming margins to 55% from 58%, while operating expenses eased 2% to $0.9M, yielding a slim operating loss of $20K versus $28K income last year. Net loss hit $41K, widened by $18K higher interest from debt, against prior profit; diluted EPS stayed flat at $(0.00) on 11.9M shares, with no dilution as options proved antidilutive. Cash drained to $48K after $116K operating outflow, but $1.2M working capital and $680K line availability buffer liquidity, alongside $320K line debt, $149K EIDL at 3.75%, and $60K equipment notes at 5-6%. FDA oversight on manufacturing looms as a key risk.
IPO
Website
Employees
Sector
Industry
AORT
Artivion, Inc.
45.91+0.54
ATRC
AtriCure, Inc.
41.08+0.04
CV
CapsoVision, Inc.
12.00-1.78
ENOV
Enovis Corporation
26.07-0.47
ISRG
Intuitive Surgical, Inc.
554.58-4.94
MMSI
Merit Medical Systems, Inc.
86.85+0.44
NOVT
Novanta Inc.
121.36+1.95
POCI
Precision Optics Corporation, I
4.20-0.07
UEEC
United Health Products, Inc.
0.06+0.00
VTAK
Catheter Precision, Inc.
2.19-0.04